41.1k views
0 votes
Which of the following asthma therapies is a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling?

A) Dupilumab
B) Reslizumab
C) Mepolizumab
D) Benralizumab

User Stoogy
by
8.4k points

1 Answer

3 votes

Final answer:

Option A. Dupilumab is the correct answer, as it is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, and is used in the treatment of moderate-to-severe asthma.

Step-by-step explanation:

The monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, which are involved in asthma pathophysiology, is Dupilumab. Therefore, the correct answer is A) Dupilumab. This medication is designed to target and block the IL-4 receptor alpha subunit, thus inhibiting the action of IL-4 and IL-13, which are key drivers of Type 2 inflammation that can contribute to several diseases, including asthma.

Dupilumab is administered by subcutaneous injection and is used in the treatment of moderate-to-severe asthma in patients who are inadequately controlled on their current asthma medications. Dupilumab is the correct answer, as it is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, and is used in the treatment of moderate-to-severe asthma.

User Jmblackmer
by
7.8k points

Related questions

asked Oct 7, 2019 227k views
Patcon asked Oct 7, 2019
by Patcon
8.9k points
2 answers
0 votes
227k views
asked May 9, 2024 80.1k views
Daf asked May 9, 2024
by Daf
7.9k points
1 answer
1 vote
80.1k views
asked Aug 6, 2024 184k views
TheMP asked Aug 6, 2024
by TheMP
7.7k points
1 answer
3 votes
184k views